In vivo growth-inhibitory effect of co-treatment of ZOL with TMZ on MGMT-expressing malignant glioma xenografts.
A, Anti-tumor effect of TMZ and ZOL combination in human malignant glioma LN-18 cell line. BALB/cA nude mice (female, 5–6 weeks old) bearing LN-18 tumor were separated into four treatment groups; None, TMZ, ZOL and TMZ + ZOL. TMZ (10 mg/kg) was administered i.p. on day 1, 2, 3, 4, 5. ZOL (5 mg/kg) was injected i.p. on day 1, 3, 5 of each week for 2 weeks. At day 35, combination of TMZ and ZOL apparently inhibited tumor growth of LN-18. B, Anti-tumor effect of TMZ and ZOL combination in human malignant glioma LN-18 cell line. Left BALB/cA nude mice bearing LN-18 tumor were treated with or without TMZ and/or ZOL. Tumor length and width were measured in situ with digital calipers once a week for 5 weeks (35 days). Tumor volume was calculated once a week for 5 weeks (35 days) according to the following equation: tumor volume (mm3) = π/6×length× (width)2. Points represent mean values ± SE. Combination of TMZ and ZOL significantly inhibited tumor growth of LN-18. Right In the same experiment as Left, body weight was measured once a week for 5 weeks (35 days). Points represent mean values ± SE. Approximate 10% body weight loss occurred in treated mice, whereas body weight was recovered during the observation period.
